stockrowbioAffinity Technologies, Inc.
BIAF Healthcare Diagnostics & Research
bioAffinity Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 million, down 34.2% from fiscal 2024.
- Revenue
- +19.0%
- EPS
- +87.5%
- Free cash flow
- −23.7%
- Total debt
- +569.7%
Quarter to June 2026, against a year earlier
Follow BIAF
Alert me
bioAffinity Technologies, Inc. (BIAF) EV/Sales
As of 5 November 2026, bioAffinity Technologies, Inc. (BIAF) trades at a EV/Sales of −0.2×. Over the past ten years it has ranged from −0.9× (December 2025) to 1,342× (May 2023); the current reading is higher than 11% of that period. That is below the Diagnostics & Research industry median of 5.2× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.6× | — |
| FY2024 | 1.1× | (78.33%) |
| FY2023 | 5.2× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.4× | (84.57%) |
| Mar 2026 | 2.6× | — |
| Dec 2025 | −0.6× | — |
| Sep 2025 | −0.6× | — |
| 13 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DMTKQ DermTech, Inc. compare | −2.5× |
| ISPC iSpecimen Inc. compare | −1.5× |
| BIAF bioAffinity Technologies, Inc. | −0.2× |
| XWEL XWELL, Inc. compare | −0.1× |
| ADVB Advanced Biomed Inc. compare | n/m |
| AWHL Aspira Women's Health Inc. compare | 1.2× |
| PRPH ProPhase Labs, Inc. compare | 1.8× |
| NDRA ENDRA Life Sciences Inc. compare | 1.9× |
| TTOO T2 Biosystems, Inc. compare | 6.3× |
| Diagnostics & Research industry median | 5.2× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)